148 related articles for article (PubMed ID: 26177208)
1. Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2.
Park SH; Park S; Kim DY; Pyo A; Kimura RH; Sathirachinda A; Choy HE; Min JJ; Gambhir SS; Hong Y
PLoS One; 2015; 10(7):e0132976. PubMed ID: 26177208
[TBL] [Abstract][Full Text] [Related]
2. Engineering of monobody conjugates for human EphA2-specific optical imaging.
Kim MA; Yoon HS; Park SH; Kim DY; Pyo A; Kim HS; Min JJ; Hong Y
PLoS One; 2017; 12(7):e0180786. PubMed ID: 28686661
[TBL] [Abstract][Full Text] [Related]
3. Production of
Pyo A; You SH; Sik Kim H; Young Kim J; Min JJ; Kim DY; Hong Y
Bioorg Med Chem Lett; 2020 Jul; 30(14):127262. PubMed ID: 32527560
[TBL] [Abstract][Full Text] [Related]
4. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies.
Lipovsek D; Lippow SM; Hackel BJ; Gregson MW; Cheng P; Kapila A; Wittrup KD
J Mol Biol; 2007 May; 368(4):1024-41. PubMed ID: 17382960
[TBL] [Abstract][Full Text] [Related]
5. High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.
Ullman C; Mathonet P; Oleksy A; Diamandakis A; Tomei L; Demartis A; Nardi C; Sambucini S; Missineo A; Alt K; Hagemeyer CE; Harris M; Hedt A; Weis R; Gehlsen KR
PLoS One; 2015; 10(8):e0135278. PubMed ID: 26313909
[TBL] [Abstract][Full Text] [Related]
6. Directed Evolution of a Highly Specific FN3 Monobody to the SH3 Domain of Human Lyn Tyrosine Kinase.
Huang R; Fang P; Hao Z; Kay BK
PLoS One; 2016; 11(1):e0145872. PubMed ID: 26731115
[TBL] [Abstract][Full Text] [Related]
7. Fibronectin type III domain based monobody with high avidity.
Duan J; Wu J; Valencia CA; Liu R
Biochemistry; 2007 Nov; 46(44):12656-64. PubMed ID: 17929945
[TBL] [Abstract][Full Text] [Related]
8. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold.
Koide A; Wojcik J; Gilbreth RN; Hoey RJ; Koide S
J Mol Biol; 2012 Jan; 415(2):393-405. PubMed ID: 22198408
[TBL] [Abstract][Full Text] [Related]
9. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain.
Koide A; Koide S
Methods Mol Biol; 2007; 352():95-109. PubMed ID: 17041261
[TBL] [Abstract][Full Text] [Related]
10. Mutational and biophysical robustness in a prestabilized monobody.
Chandler PG; Tan LL; Porebski BT; Green JS; Riley BT; Broendum SS; Hoke DE; Falconer RJ; Munro TP; Buckle M; Jackson CJ; Buckle AM
J Biol Chem; 2021; 296():100447. PubMed ID: 33617878
[TBL] [Abstract][Full Text] [Related]
11. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
[TBL] [Abstract][Full Text] [Related]
12. A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein.
Matsui H; Sakurai F; Katayama K; Abe Y; Machitani M; Kurachi S; Tachibana M; Mizuguchi H
Biomaterials; 2013 May; 34(16):4191-4201. PubMed ID: 23473963
[TBL] [Abstract][Full Text] [Related]
13. Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain.
Chandler PG; Buckle AM
Cells; 2020 Mar; 9(3):. PubMed ID: 32143310
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin.
Gebauer M; Schiefner A; Matschiner G; Skerra A
J Mol Biol; 2013 Feb; 425(4):780-802. PubMed ID: 23238252
[TBL] [Abstract][Full Text] [Related]
16. High-affinity single-domain binding proteins with a binary-code interface.
Koide A; Gilbreth RN; Esaki K; Tereshko V; Koide S
Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6632-7. PubMed ID: 17420456
[TBL] [Abstract][Full Text] [Related]
17. Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo.
Lee CH; Park KJ; Sung ES; Kim A; Choi JD; Kim JS; Kim SH; Kwon MH; Kim YS
Proc Natl Acad Sci U S A; 2010 May; 107(21):9567-71. PubMed ID: 20460308
[TBL] [Abstract][Full Text] [Related]
18. EDB Fibronectin Specific Peptide for Prostate Cancer Targeting.
Han Z; Zhou Z; Shi X; Wang J; Wu X; Sun D; Chen Y; Zhu H; Magi-Galluzzi C; Lu ZR
Bioconjug Chem; 2015 May; 26(5):830-8. PubMed ID: 25848940
[TBL] [Abstract][Full Text] [Related]
19. FN3: a new protein scaffold reaches the clinic.
Bloom L; Calabro V
Drug Discov Today; 2009 Oct; 14(19-20):949-55. PubMed ID: 19576999
[TBL] [Abstract][Full Text] [Related]
20. Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain.
Batori V; Koide A; Koide S
Protein Eng; 2002 Dec; 15(12):1015-20. PubMed ID: 12601141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
